DSE/SQURPHARMA (DSE/SQURPHARMA)

Dhaka Stock Exchange: DSE/SQURPHARMA · BDT

BDT 219

+0.00 (0.0%)· Recorded snapshot

Market cap	194B
Revenue (ttm)	83.5B
Net income (ttm)	25.9B
EPS (ttm)	BDT 29.2
Shares out	886.5M
P/E (trailing)	7.5x
P/E (forward)	6.8x
Dividend	BDT 12.0 (5.48%)
Volume	238,797
Beta	0.11

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 83.5B
Net income (ttm): 25.9B
EPS (ttm): BDT 29.2
P/E (trailing): 7.5x
P/E (forward): 6.8x
Market cap: 194B

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-29 13:30 UTC

Forward P/E6.8

P25 n/aP50 n/aP75 n/a

Trailing P/E7.5

P25 n/aP50 n/aP75 n/a

ROE18.1

P25 n/aP50 n/aP75 n/a

ROIC20.5

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All DSE/SQURPHARMA indicators

Market & fundamental data

Available fields

249

Groups with data

Currency

BDT

Showing 249 of 249 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	BDT
Country	Bangladesh
Country code	BD
Earnings date	2026-10-29
Employees	15,937
Employees change	3,484
Employees growth	27.98%
Enterprise value	BDT 121.7B
Exchange	Dhaka Stock Exchange
Financial currency	BDT
Financial report date	2026-03-31
First seen	2026-05-10
Fiscal year end	June
Founded	1958
Industry	Pharmaceutical Preparations
Is primary listing	Yes
ISIN number	BD0473SQPH00
Last earnings date	2026-04-29
Last refreshed	2026-10-29
Last stock split date	2020-11-23
Last stock split type	Forward
Market cap	BDT 194B
Price	BDT 218.80
Price currency	BDT
SIC code	2834
Stock price date	2026-10-28
Symbol	dse/SQURPHARMA
Website	https://www.squarepharma.com.bd

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Average P/E ratio (10Y)	12.72x
Average P/E ratio (3Y)	8.6x
Average P/E ratio (5Y)	9.45x
Earnings yield	13.33%
EV/Earnings	4.71x
EV/EBIT	4.97x
EV/EBITDA	4.56x
EV/FCF	8.71x
EV/Sales	1.46x
FCF / EV yield	11.48%
FCF yield	7.21%
Forward P/E	6.77x
Graham number	333.84496
Graham upside	52.58%
Industry P/E	9.79x
Lynch fair value	BDT 358.69
Lynch upside	63.93%
P/B ratio	1.29x
P/E ratio	7.5x
P/FCF ratio	13.88x
P/OCF ratio	8.7x
P/S ratio	2.32x
Price / tangible book value	1.29x
Price/EBITDA ratio	8.07x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	26.12%
EBITDA margin	28.77%
Effective tax rate	17.93%
FCF margin	16.74%
Gross margin	48.24%
Operating margin	26.12%
Pretax margin	37.73%
Profit margin	30.96%
Profit per employee	BDT 1.6M
Revenue per employee	BDT 5.2M
ROA	9.1%
ROA (5Y)	9.47%
ROCE	14.36%
ROE	18.14%
ROE (5Y)	18.02%
ROIC	20.48%
ROIC (5Y)	22.82%
Tax / revenue	6.77%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	10.04%
EPS growth (Q)	-1.46%
EPS growth (QoQ)	-17.93%
EPS growth 10Y	12.78%
EPS growth 3Y	11.11%
EPS growth 5Y	12.29%
FCF growth	70.62%
FCF growth (Q)	-53.39%
FCF growth (QoQ)	-63.91%
FCF growth 3Y	26.12%
FCF growth 5Y	13.74%
Gross profit growth	16.02%
Gross profit growth (Q)	7.3%
Gross profit growth 3Y	9.56%
Gross profit growth 5Y	10.6%
Net income growth	10.04%
Net income growth (Q)	-1.41%
Net income growth (QoQ)	-17.96%
Net income growth 3Y	11.11%
Net income growth 5Y	12.29%
OCF growth	62.5%
OCF growth (Q)	20.89%
OCF growth (QoQ)	-21.91%
OCF growth 10Y	8.92%
OCF growth 3Y	29.41%
OCF growth 5Y	16.16%
Operating income growth	20.44%
Operating income growth (Q)	0.39%
Operating income growth 3Y	8.59%
Operating income growth 5Y	7.78%
Revenue growth	10.11%
Revenue growth (Q)	7.83%
Revenue growth (QoQ)	-0.42%
Revenue growth 10Y	10.92%
Revenue growth 3Y	10.43%
Revenue growth 5Y	11.25%

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	BDT -8.3B
Depreciation and amortization	BDT 2.2B
EBIT	BDT 21.8B
EBITDA	BDT 24B
EPS	BDT 29.18
FCF per share	BDT 15.77
Financing cash flow	BDT -11.2B
Free cash flow	BDT 14B
Gross profit	BDT 40.3B
Income taxes	BDT 5.7B
Investing cash flow	BDT -7.8B
Net borrowing	BDT -621.8M
Net cash flow	BDT 3.3B
Net income	BDT 25.9B
Operating income	BDT 21.8B
Revenue	BDT 83.5B

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	18.17
Book value per share	BDT 169.78
Debt / EBITDA	0.01
Debt / equity	0
Debt / FCF	0.03
Interest coverage	185.75
Long-term assets	BDT 75.3B
Long-term liabilities	BDT 1.4B
Net cash (debt)	BDT 72.2B
Net cash / market cap	37.23%
Net cash growth	22.26%
Net debt / EBITDA	-3.01
Net debt / equity	-0.48
Net debt / FCF	-5.17
Piotroski F-Score	5
Property, plant and equipment	BDT 36.9B
Shareholders' equity	BDT 150.5B
Tangible book value	BDT 150.5B
Tangible book value per share	BDT 169.78
Total assets	BDT 157.9B
Total cash	BDT 60.8B
Total debt	BDT 356M
Total liabilities	BDT 7.4B
WACC	4.91%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.56
Current assets	BDT 82.6B
Current liabilities	BDT 6B
Current ratio	13.78
Inventory turnover	3.19
Net working capital	BDT 16.1B
Quick ratio	11.26
Working capital	BDT 76.6B
Working capital turnover	1.15

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend growth	8.33%
Dividend growth (10Y)	15.43%
Dividend growth (3Y)	7.38%
Dividend growth (5Y)	16.72%
Dividend growth years	8
Dividend payment date	2027-01-14
Dividend payment years	24
Dividend payout frequency	Annual
Dividend per share	BDT 12.00
Dividend yield	5.48%
Ex-dividend date	2026-11-17
FCF payout ratio	82.44%
Last dividend	BDT 13.00
Payout ratio	40.97%
Shareholder yield	5.48%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	15.71%
10Y return CAGR	4.72%
10Y total return	58.61%
150-day SMA	BDT 216.43
15Y price change	202.57%
15Y return CAGR	10.26%
15Y total return	333.01%
1D price change	0%
1M price change	0.64%
1M total return	0.64%
1W price change	-0.05%
1W total return	-0.05%
1Y price change	2.1%
1Y return CAGR	8.2%
1Y total return	8.19%
20-day SMA	BDT 218.33
200-day SMA	BDT 215.99
20Y price change	1,375.99%
20Y return CAGR	16.77%
20Y total return	2,120.55%
3M price change	0.18%
3M total return	0.18%
3Y price change	3.75%
3Y return CAGR	6.77%
3Y total return	21.7%
50-day SMA	BDT 217.21
50-day SMA vs 200-day SMA	50over200
52-week high	BDT 236.00
52-week high date	2026-02-16
52-week low	BDT 198.00
52-week low date	2026-01-01
5Y price change	-0.64%
5Y return CAGR	4.68%
5Y total return	25.66%
6M price change	2.97%
6M total return	2.97%
All-time high	BDT 278.67
All-time high date	2018-01-22
All-time low	BDT 0.74
All-time low date	1996-07-10
Average true range (ATR)	BDT 1.58
Average volume	219.1K
Beta (1Y)	0.16
Beta (2Y)	0.08
Beta (5Y)	0.11
Change from 52-week high	-7.29%
Change from 52-week low	10.51%
Change from all-time high	-21.48%
Change from all-time low	29,575.84%
Change from open	-0.05%
Day's gap	0.05%
Dollar volume	BDT 52.2M
High price	BDT 219.20
Low price	BDT 218.20
Monthly RSI	51.98
Open price	BDT 218.90
Position in 52-week range	60%
Previous close	BDT 218.80
Price vs 150-day SMA	1.09%
Price vs 20-day SMA	0.22%
Price vs 200-day SMA	1.3%
Price vs 50-day SMA	0.73%
Relative volume	1.09
RSI	55.88
Sharpe ratio	0.5
Sharpe ratio (3Y)	0.29
Sharpe ratio (5Y)	0.08
Sortino ratio	1.38
Sortino ratio (3Y)	1.04
Sortino ratio (5Y)	0.7
Volume	238.8K
Weekly RSI	98.98
YTD price change	10.17%
YTD total return	10.17%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	495.5M
Shares change (QoQ)	-0.04%
Shares held by insiders	44.1%
Shares held by institutions	3.02%
Shares outstanding	886.5M

Deeper analysis on DSE/SQURPHARMA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this DSE/SQURPHARMA report

Is a complete DSE/SQURPHARMA research report available?

No complete published report is available for dse/SQURPHARMA (DSE/SQURPHARMA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

DSE/SQURPHARMA (DSE/SQURPHARMA)

Price

Financial snapshot

Fair-value bridge

Latest news · DSE/SQURPHARMA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All DSE/SQURPHARMA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on DSE/SQURPHARMA

Frequently asked questions